Hinweise zu Qualitätskriterien von Zeitschriften
Open-Access-Richtlinie der Helmholtz-Gemeinschaft 2016
CC Licencences
Metriken für Publikationen
Startseite
Login
English
Neuer EVA Antrag
Erweiterte Suche
Durchblättern nach ...
Publikationen im Überblick
HGF Fortschrittsbericht
OA Publikationen
Neue Publikation eintragen
Neue Publikation holen aus...
Fehlende Publikation melden
Ansprechpartner
Hilfe
Bibliometrische Indikatoren
Text
Endnote (RIS)
BibTeX
Verlagsversion
DOI
PMC
 |
Open Access Hybrid |
möglich sobald bei der ZB eingereicht worden ist.
A Modified Mediterranean Ketogenic Diet reverses signaturesand mitigates modifiable risk factors of Alzheimer’s disease.
In:. New York, NY [u.a.]: Elsevier, 2024.:e089878 (Alzheimers Dement. ; 20 Suppl 7)
BACKGROUND: Alzheimer's disease (AD) is a neurodegenerative disorder with significant environmental factors, including diet, that influence its onset and progression. While the ketogenic diet (KD) holds promise in reducing metabolic risks and potentially affecting AD progression, only a few studies have explored the KD's molecular impact for markers of AD therapeutic potential. The BEAM diet study simultaneously profiled the KD's effect on the lipidome, blood and cerebrospinal metabolome, and microbiome of both cognitively impaired and cognitively normal individuals. The findings summarized here assess the biological impact of a Modified Mediterranean KD in the context of Alzheimer's disease treatment and prevention. METHOD: BEAM involved participants at risk for AD, either cognitively normal or with mild cognitive impairment. The participants consumed both a modified Mediterranean-ketogenic diet (MMKD) and the American Heart Association diet (AHAD) for 6 weeks each, separated by a 6-week washout period. We employed HPLC-MS/MS lipidomics profiling in plasma, nuclear magnetic resonance (NMR)-based metabolomics to profile serum and CSF, and metagenomics profiling on fecal samples before and after each diet to assess dietary-induced changes. RESULT: The MMKD led to significant alterations in the blood, CSF, and microbiome. These changes included a global elevation across all plasmanyl and plasmenyl ether lipid species, improved modifiable risk factors, like increased HDL-C and reduced BMI, the reversal of serum metabolic disturbances linked to AD such as an increase in valine levels, and a reduction in systemic inflammation. Leveraging prior clinical studies on AD (n = 1,912), we found that MMKD was inversely associated with the peripheral lipidomic signature of prevalent and incident AD. In the CSF, the MMKD was linked to modified amino acid levels and the breakdown of branched-chain amino acids (BCAAs). Importantly, we observed a strong correlation between metabolic changes in the CSF and serum, suggesting a systemic regulation of metabolism. In addition, participants with MCI on the MMKD had lower levels of GABA-producing microbes and GABA, and higher levels of GABA-regulating microbes. CONCLUSION: Our findings highlight that MMKD can improve AD-related risk factors, reverse some metabolic disturbances associated with AD, and align metabolic changes across the blood-CSF barrier. FUNDING: Alzheimer's Gut Microbiome Project, NIA U19AG063744.
Altmetric
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern
Publikationstyp
Artikel: Konferenzbeitrag
Sprache
englisch
Veröffentlichungsjahr
2024
HGF-Berichtsjahr
2025
ISSN (print) / ISBN
1552-5260
e-ISSN
1552-5279
Zeitschrift
Alzheimer's & Dementia
Quellenangaben
Band: 20 Suppl 7,
Artikelnummer: e089878
Verlag
Elsevier
Verlagsort
New York, NY [u.a.]
Begutachtungsstatus
Peer reviewed
Institut(e)
Institute of Computational Biology (ICB)
POF Topic(s)
30205 - Bioengineering and Digital Health
Forschungsfeld(er)
Enabling and Novel Technologies
PSP-Element(e)
G-503891-001
PubMed ID
39784512
Erfassungsdatum
2025-04-03